Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Targets
  4. Volume 21, Issue 12
  5. Article
Volume 21, Issue 12
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

This review focuses on 5 new anti-VEGF drugs in the advanced stage of clinical development (i.e., phase 3): conbercept, brolucizumab, port delivery system with ranibizumab, abicipar pegol and faricimab. Results of clinical trials and the advantages of each drug compared to the available molecules are discussed in detail.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450121666200428101738
2020-09-01
2025-05-05

  • From This Site

    /content/journals/cdt/10.2174/1389450121666200428101738
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450121666200428101738
Loading

  • Article Type:     Review Article
Keyword(s): abicipar pegol; Anti-VEGF; brolucizumab; conbercept; faricimab; port delivery system; ranibizumab

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test